表紙
市場調查報告書
商品編碼
1035999

世界神經系統疾病治療的增長機會

Global Neurological Therapies Growth Opportunities

出版日期: | 出版商: Frost & Sullivan | 英文 61 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

由於需要有效的姑息治療,開髮用於治療神經系統疾病的藥物的技術正在改進。此外,學術機構、公共機構、私營公司等正在開發治療神經退行性疾□□病的新技術。

神經退行性疾□□病的複雜性、對疾病機制的理解、缺乏改變疾病的治療方案、多種疾病病理等被認為是治療神經退行性疾□□病以及製造、分銷、藥物遞送的主要挑戰跨越血腦屏障是開發神經退行性疾□□病治療劑的挑戰之一。

本報告調查了全球神經系統疾病的治療方法,包括神經系統疾病概述、神經退行性疾□□病的新療法、藥物輸送系統、行業舉措和知識產權條件、活躍公司和增長機會。我們提供的信息包括.

目錄

第 1 章戰略義務

  • 增長困難,戰略要務 8 (TM):對增長造成壓力的因素
  • 戰略要務 8 (TM)
  • 三大戰略需求對神經治療行業技術進步的影響
  • 增長機會推動增長管道引擎 (TM)
  • 調查方法

第二章成長環境

  • 神經系統疾病:概述
  • 神經退行性疾□□病:全球健康危機
  • 調查範圍
  • 需要高效且具有成本效益的解決方案
  • 業界致力於解決關鍵問題
  • 行業旨在早期干預和預防神經退行性疾□□病

第 3 章神經退行性疾□□病的新療法

  • 為應對挑戰而研發的新療法
  • 新一代口服小分子療法研究
  • 處於臨床試驗後期階段的小分子療法
  • 開發專注於治療阿爾茨海默病的先進生物製劑
  • 錯誤折疊的蛋白質聚集體是管道中抗體的主要目標
  • 核酸療法被認為是一種可持續的治療選擇
  • 專注於帕金森病和肌萎縮側索硬化症的核酸療法
  • 幹細胞被認為是克服神經退行性疾□□病的有效療法
  • 研究用於對抗神經變性的個性化細胞療法
  • 新治療方法的比較評價

第 4 章有效給藥的給藥系統

  • 研究可能跨越血腦屏障的新興遞送方法
  • 給藥系統的主要發展

第 5 章行業舉措和 IP 形勢

  • 專注於克服行業內未滿足的神經退行性疾□□病治療需求
  • 神經科學行業的戰略措施
  • 神經退行性疾□□病專利情況
  • 專利分析顯示藥物開發穩步推進

第 6 章活躍公司

  • 頭腦風暴細胞療法
  • Ionis Pharmaceuticals Inc.
  • MediciNova Inc.
  • AB Science S.A.
  • Alzheon Inc.
  • Alector Inc.
  • Athira Pharma Inc.
  • Seelos Therapeutics, Inc.
  • BioArctic AB

第 7 章增長機會的宇宙

  • 生長機會 1:防止蛋白質聚集體形成的處理
  • 增長機會 2:加速用於診斷和新藥發現的生物標誌物發現
  • 增長機會:通過血腦屏障的藥物輸送策略

第8章附錄

  • 與單克隆抗體相關的臨床試驗
  • 專注於基因治療的臨床試驗

第 9 章後續步驟

目錄
Product Code: DA0D

Need for Effective Palliative Management Driving Technology Advances in Neurological Disease Drug Development

Neurological diseases refer to disorders of the brain, nerves, and spinal cord that lead to structural, biochemical, or electrical complications in the body. Major causes of neurological disorders include brain, spinal cord, or nerve injury; genetic disorders; congenital abnormalities; infections; and lifestyle. Neurological diseases include an extensive scope of disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, autism, neuromuscular disorders, brain tumors, and cerebral palsy. Some neurological disorders that are congenital emerge before birth. Other diseases are caused by trauma, infections, tumors, neurodegeneration, or structural defects. The pharmaceutical industry is spending a huge amount on developing novel technologies as treatment for neurodegenerative diseases.

Among the hardest neurological disorders to cure and that have devastating outcomes are neurodegenerative diseases. Neurodegenerative diseases are a diverse group of disorders that involve progressive degeneration of the structure and function of the central or peripheral nervous system. Two of the most common neurodegenerative diseases are Alzheimer's disease and Parkinson's disease, which affect millions of people worldwide.

The complex nature of neurodegenerative disorders, minimal understanding of disease mechanisms, lack of disease modifying treatment solutions, and multiple disease pathologies are some of the main challenges discussed in this report. Moreover, manufacturing, logistics, and drug delivery across the blood-brain barrier are other challenges in developing potential drugs for neurodegenerative disorders.

Academic institutions, public and private organizations, and companies are developing novel technologies to cure neurodegenerative diseases. Frost & Sullivan has identified technological advancements in the following established therapies: small molecules, advanced biologics, nucleic acid therapy, and cell therapy.

This research has identified novel approaches that are being developed to deliver drugs across blood-brain barrier. Also, strategic decisions being taken in the neuroscience industry are highlighted in the report. Patents for the technologies being developed to treat neurodegenerative disorders are discussed.

The competitive landscape and product pipeline analysis of companies focusing specifically on therapeutic interventions for neurodegenerative diseases are evaluated. Growth opportunities along with recommended actions for the companies involved in the global neurodegenerative therapy space are discussed in this research study.

Key Points Addressed:

  • 1. Major neurodegenerative diseases and challenges in treating them
  • 2. Emerging therapies for neurodegenerative diseases
  • 3. Novel drug delivery systems and key advancements
  • 4. Industry landscape and patent filing trends
  • 5. Key growth opportunities for industry players

Table of Contents

1.0 Strategic Imperatives

  • 1.1 Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
  • 1.2 The Strategic Imperative 8™
  • 1.3 The Impact of the Top Three Strategic Imperatives on Technology Advances in Neurological Therapies Industry
  • 1.4 Growth Opportunities Fuel the Growth Pipeline Engine™
  • 1.5 Research Methodology

2.0 Growth Environment

  • 2.1 Neurological Diseases: An Overview
  • 2.2 Neurodegenerative Diseases: A Global Health Crisis
  • 2.3 Research Scope
  • 2.4 Need for Efficient and Cost-effective Solutions
  • 2.5 Industry Addressing Key Challenges
  • 2.6 Industry Targeting Early Intervention and Prevention of Neurodegenerative Diseases

3.0 Emerging Therapies for Treatment of Neurodegenerative Diseases

  • 3.1 Emerging Therapies in the Pipeline to Address Challenges
  • 3.2 Research on Next-gen Small Molecule Therapies through Oral Administration
  • 3.3 Small Molecule Therapies in Advanced Stages of Clinical Trials
  • 3.4 Developments in Advanced Biologics Focus on Treating Alzheimer's
  • 3.5 Misfolded Protein Aggregates as the Main Target of Antibodies in Pipeline
  • 3.6 Nucleic Acid Therapy Considered a Sustainable Treatment Option
  • 3.7 Nucleic Acid Therapy Focused on Parkinson's Disease and ALS
  • 3.8 Stem Cells Considered a Potent Therapeutic to Overcome Neurodegeneration
  • 3.9 Personalized Cell Therapies Researched to Address Neurodegeneration
  • 3.10 Comparative Assessment of Emerging Therapies

4.0 Delivery Systems for Effective Drug Administration

  • 4.1 Research on Emerging Delivery Approaches with Potential to Cross the BBB
  • 4.2 Key Developments in Drug Delivery Systems

5.0 Industry Efforts and IP Landscape

  • 5.1 Industry Focused on Overcoming Unmet Needs for Treating Neurodegenerative Diseases
  • 5.2 Strategic Measures in Neuroscience Industry
  • 5.3 Patent Landscape for Neurodegenerative Diseases
  • 5.4 Patent Analysis Shows Steady Efforts towards Drug Development

6.0 Companies to Action

  • 6.1 Brainstorm Cell Therapeutics
  • 6.2 Ionis Pharmaceuticals Inc.
  • 6.3 MediciNova Inc.
  • 6.4 AB Science S.A.
  • 6.5 Alzheon Inc.
  • 6.6 Alector Inc.
  • 6.7 Athira Pharma Inc.
  • 6.8 Seelos Therapeutics, Inc.
  • 6.9 BioArctic AB

7.0 Growth Opportunity Universe

  • 7.1 Growth Opportunity 1: Therapies Preventing Protein Aggregate Formation
  • 7.1 Growth Opportunity 1: Therapies Preventing Protein Aggregate Formation (continued)
  • 7.2 Growth Opportunity 2: Accelerate Biomarker Discovery for Diagnostics and Novel Drug Discovery
  • 7.2 Growth Opportunity 2: Accelerate Biomarker Discovery for Diagnostics and Novel Drug Discovery (continued)
  • 7.3 Growth Opportunity: Strategies for Drug Delivery through the Blood-Brain Barrier
  • 7.3 Growth Opportunity: Delivery Strategies through Blood-Brain Barrier (continued)

8.0 Appendix

  • 8.1 Clinical Trials Related to Monoclonal Antibodies
  • 8.2 Clinical Trials Focusing on Gene Therapies

9.0 Next Steps

  • 9.1 Your Next Steps
  • 9.2 Why Frost, Why Now?
  • Legal Disclaimer